Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $1,910,168.76 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 33,284 shares of the stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $57.39, for a total transaction of $1,910,168.76. Following the transaction, the chief executive officer directly owned 167,763 shares in the company, valued at approximately $9,627,918.57. This represents a 16.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Fukushima also recently made the following trade(s):

• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00.
• On Tuesday, May 19th, Ryan Fukushima sold 13,550 shares of Tempus AI stock. The shares were sold at an average price of $44.07, for a total transaction of $597,148.50.

Tempus AI Stock Performance

NASDAQ TEM opened at $58.23 on Monday. The company has a 50-day simple moving average of $51.29 and a two-hundred day simple moving average of $54.27. Tempus AI, Inc. has a 12-month low of $41.73 and a 12-month high of $104.32. The firm has a market cap of $10.46 billion, a price-to-earnings ratio of -33.85 and a beta of 3.46. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm had revenue of $348.12 million for the quarter, compared to the consensus estimate of $345.44 million. During the same quarter in the previous year, the business earned ($0.24) earnings per share. The company’s quarterly revenue was up 36.1% on a year-over-year basis. On average, equities analysts forecast that Tempus AI, Inc. will post -1.35 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. JPL Wealth Management LLC purchased a new stake in Tempus AI in the 3rd quarter worth approximately $26,000. Los Angeles Capital Management LLC purchased a new position in shares of Tempus AI during the fourth quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd purchased a new position in shares of Tempus AI during the third quarter valued at approximately $38,000. Danske Bank A S bought a new position in shares of Tempus AI during the third quarter valued at approximately $48,000. Finally, Sunbelt Securities Inc. bought a new position in shares of Tempus AI during the third quarter valued at approximately $52,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Freedom Capital raised Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. HC Wainwright dropped their price objective on Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Jefferies Financial Group started coverage on shares of Tempus AI in a report on Monday, April 13th. They issued an “underperform” rating and a $35.00 target price on the stock. BTIG Research reaffirmed a “buy” rating and issued a $80.00 target price on shares of Tempus AI in a research note on Monday, June 1st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $75.00 price target on shares of Tempus AI in a report on Monday, June 1st. Nine equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Tempus AI has a consensus rating of “Hold” and a consensus price target of $68.54.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.